Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: Control of the incretin axis and regulation of postprandial glucose and lipid metabolism

EE Mulvihill - Peptides, 2018 - Elsevier
Abstract Dipeptidyl peptidase 4 (DPP4) is a widely expressed, serine protease which
regulates the bioactivity of many peptides through cleavage and inactivation including the
incretin hormones, glucagon like peptide− 1 (GLP-1) and glucose dependent insulinotropic
polypeptide (GIP). Inhibitors of DPP4 are used therapeutically to treat patients with Type 2
Diabetes Mellitus (T2DM) as they potentiate incretin action to regulate islet hormone
secretion and improve glycemia and post-prandial lipid excursions. The widespread clinical …